Skip to main content
Erschienen in: Endocrine Pathology 1/2018

02.02.2018

The Prevalence of Extranodal Extension in Papillary Thyroid Cancer Based on the Size of the Metastatic Node: Adverse Histologic Features Are Not Limited to Larger Lymph Nodes

verfasst von: Meghan E. Rowe, Umut Ozbek, Rosalie A. Machado, Lauren E. Yue, Juan C. Hernandez-Prera, Alessandro Valentino, Muhammad Qazi, Margaret Brandwein-Weber, Xulei Liu, Bruce M. Wenig, Mark L. Urken

Erschienen in: Endocrine Pathology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Extranodal extension (ENE) is a prognostic indicator of aggressiveness for papillary thyroid cancer (PTC). The association between the size of metastatic nodes and the prevalence of ENE has not been previously explored. However, there is a common belief that small lymph nodes with metastatic disease do not significantly impact patient outcome. This study investigates the relationship between the prevalence of ENE and the size of a positive lymph node. Linear dimensions and malignant histological characteristics of 979 metastatic lymph nodes from 152 thyroid cancer patients were retrospectively analyzed. Data was analyzed using chi-square tests and multilevel logistic regression modeling. ENE was present in 144 of 979 lymph nodes; the sizes of the involved lymph nodes ranged from 0.9 to 44 mm. ENE was identified in 7.8% of lymph nodes measuring ≤ 5 mm, 18.9% between 6 and 10 mm, 23.1% between 11 and 15 mm, 25.0% between 16 and 20 mm, and 14.0% between 21 and 25 mm in size. The association between node size and ENE status was significant (odds ratio (OR) = 1.07, confidence interval (CI) = [1.04, 1.11]). The size of the metastatic focus directly correlated with ENE (OR = 1.07, 95% CI = [1.07, 1.14], p value < 0.001). Increasing lymph node size increases the likelihood of ENE for metastatic PTC. Importantly, small positive lymph nodes can also harbor ENE to a significant extent. Further studies are required to determine the clinical and prognostic significance of lymph node size and the presence of ENE.
Literatur
1.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26: 1–133, 2016. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26: 1–133, 2016.
2.
Zurück zum Zitat Scherl S, Mehra S, Clain J et al. The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes: what are we missing when we don't perform a prophylactic dissection of central compartment lymph nodes in papillary thyroid cancer? Thyroid 24: 1282–1288, 2014.CrossRefPubMed Scherl S, Mehra S, Clain J et al. The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes: what are we missing when we don't perform a prophylactic dissection of central compartment lymph nodes in papillary thyroid cancer? Thyroid 24: 1282–1288, 2014.CrossRefPubMed
3.
Zurück zum Zitat Randolph GW, Duh QY, Heller KS et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22: 1144–1152, 2012.CrossRefPubMed Randolph GW, Duh QY, Heller KS et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22: 1144–1152, 2012.CrossRefPubMed
4.
Zurück zum Zitat Ito Y, Tomoda C, Uruno T et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 30: 91–99, 2006.CrossRefPubMed Ito Y, Tomoda C, Uruno T et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 30: 91–99, 2006.CrossRefPubMed
5.
Zurück zum Zitat Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135: 139–148, 2004.CrossRefPubMed Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135: 139–148, 2004.CrossRefPubMed
6.
Zurück zum Zitat Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90: 5723–5729, 2005.CrossRefPubMed Leboulleux S, Rubino C, Baudin E et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90: 5723–5729, 2005.CrossRefPubMed
7.
Zurück zum Zitat Ito Y, Hirokawa M, Jikuzono T et al. Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma. World J Surg 31: 1194–1201, 2007.CrossRefPubMed Ito Y, Hirokawa M, Jikuzono T et al. Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma. World J Surg 31: 1194–1201, 2007.CrossRefPubMed
8.
Zurück zum Zitat Lango M, Flieder D, Arrangoiz R et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid 23: 1099–1105, 2013.CrossRefPubMedPubMedCentral Lango M, Flieder D, Arrangoiz R et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid 23: 1099–1105, 2013.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 80: 2268–2272, 1997.CrossRefPubMed Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 80: 2268–2272, 1997.CrossRefPubMed
10.
Zurück zum Zitat World Medical A World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310: 2191–2194, 2013.CrossRef World Medical A World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310: 2191–2194, 2013.CrossRef
11.
Zurück zum Zitat Du E, Wenig BM, Su HK et al. Inter-observer variation in the pathologic identification of extranodal extension in nodal metastasis from papillary thyroid carcinoma. Thyroid 26: 816–819, 2016.CrossRefPubMed Du E, Wenig BM, Su HK et al. Inter-observer variation in the pathologic identification of extranodal extension in nodal metastasis from papillary thyroid carcinoma. Thyroid 26: 816–819, 2016.CrossRefPubMed
12.
Zurück zum Zitat Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148: 1100–1106; discussion 1006-1107, 2010.CrossRefPubMed Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148: 1100–1106; discussion 1006-1107, 2010.CrossRefPubMed
13.
Zurück zum Zitat Wada N, Duh QY, Sugino K et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237: 399–407, 2003.PubMedPubMedCentral Wada N, Duh QY, Sugino K et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg 237: 399–407, 2003.PubMedPubMedCentral
14.
Zurück zum Zitat Urken ML, Haser GC, Likhterov I, Wenig BM The impact of metastatic lymph nodes on risk stratification in differentiated thyroid cancer: have we reached a higher level of understanding? Thyroid 26: 481–488, 2016.CrossRefPubMed Urken ML, Haser GC, Likhterov I, Wenig BM The impact of metastatic lymph nodes on risk stratification in differentiated thyroid cancer: have we reached a higher level of understanding? Thyroid 26: 481–488, 2016.CrossRefPubMed
15.
Zurück zum Zitat Vassilopoulou-Sellin R, Schultz PN, Haynie TP Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78: 493–501, 1996.CrossRefPubMed Vassilopoulou-Sellin R, Schultz PN, Haynie TP Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78: 493–501, 1996.CrossRefPubMed
Metadaten
Titel
The Prevalence of Extranodal Extension in Papillary Thyroid Cancer Based on the Size of the Metastatic Node: Adverse Histologic Features Are Not Limited to Larger Lymph Nodes
verfasst von
Meghan E. Rowe
Umut Ozbek
Rosalie A. Machado
Lauren E. Yue
Juan C. Hernandez-Prera
Alessandro Valentino
Muhammad Qazi
Margaret Brandwein-Weber
Xulei Liu
Bruce M. Wenig
Mark L. Urken
Publikationsdatum
02.02.2018
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 1/2018
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9518-7

Weitere Artikel der Ausgabe 1/2018

Endocrine Pathology 1/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …